Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,664 across all filing types
Latest filing 2023-08-13 Regulatory Filings
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Exceptional Results in Second Valve-in-Valve Case 2 pages 156.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 14 August 2023 from Anteris Technologies Ltd. It reports on clinical results of their DurAVR™ transcatheter aortic valve in a second Valve-in-Valve procedure under Health Canada's Special Access Program. The content focuses on clinical and commercial updates about the product's performance and ongoing clinical trials. There are no financial statements, regulatory filings, or detailed financial data. The document is a corporate announcement about product clinical progress and commercial outlook rather than a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a general company announcement about clinical and commercial progress, best classified as a Regulatory Filing (RNS) as a fallback for miscellaneous announcements that do not fit other categories.
2023-08-13 English
Montefiore enrolls Patients in US Early Feasibility Study 4 pages 239.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 9 August 2023 from Anteris Technologies Ltd regarding the enrollment of patients in a US Early Feasibility Study (EFS) for their DurAVR™ Transcatheter Heart Valve. It describes clinical trial details, study design, primary and secondary outcome measures, and comments from company executives and medical investigators. The document is a corporate announcement about a clinical study milestone and does not contain financial statements, earnings data, or regulatory filings related to financial performance. It is not a report of voting results, management changes, or legal proceedings. It is also not a presentation or transcript of a call. The document is a news release about a clinical trial progress and product development milestone, which fits best under the category of a general regulatory announcement or compliance update. Given the absence of financial data or detailed report content, the most appropriate classification is Regulatory Filings (RNS). The document length (9871 characters) and content confirm it is not a brief report publication announcement or a full financial report.
2023-08-08 English
Commencement of American Depository Receipt Program 2 pages 175.7KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 9 August 2023 regarding Anteris Technologies commencing an American Depository Receipt (ADR) program. It describes the establishment of the ADR program, its purpose, and details about trading and the Depositary Bank. There is no financial data, no report attached or referenced as being published, and no mention of a report filing. The document is an announcement about a capital market activity related to the company's securities but explicitly states that no new capital is being raised. This fits the category of Capital/Financing Update (CAP) as it relates to changes in capital structure accessibility and trading instruments, not a full financial report or regulatory filing. The document length is under 5,000 characters, but it is not a report publication announcement since it does not mention any report being attached or published. Therefore, the best classification is CAP with high confidence.
2023-08-08 English
Notification regarding unquoted securities - AVR 9 pages 33.7KB
Share Issue/Capital Change Classification · 100% confidence The document is a notification regarding the issue of unquoted equity securities by Anteris Technologies Ltd. It details the number and type of securities issued, including options under an employee incentive scheme, with specific issue dates and terms. The document is structured as an official announcement to the ASX about securities issuance, not a financial report or earnings release. It does not contain financial statements or management discussion but focuses on capital changes related to securities issuance. Therefore, it fits the category of a Share Issue/Capital Change announcement.
2023-08-08 English
Notification of cessation of securities - AVR 5 pages 25.7KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Notification of cessation of +securities' and details the lapse of certain options (securities) for Anteris Technologies Ltd. It provides specific information about the securities that have ceased, the reasons for cessation, and the updated issued capital following these changes. The content is focused on changes in the company's issued securities, specifically the cessation of certain options due to conditions not being met. There is no financial performance data, no management discussion, no earnings information, no legal proceedings, or other report types. This type of announcement fits the category of Share Issue/Capital Change (SHA), as it relates to changes in the company's capital structure through cessation of securities. The document length is about 5,139 characters, which is sufficient for a detailed announcement rather than a brief notice. Therefore, the appropriate classification is SHA with high confidence.
2023-08-08 English
Notice of Extraordinary General Meeting/Proxy Form 15 pages 804.4KB
Proxy Solicitation & Information Statement Classification · 95% confidence The document is an announcement of an Extraordinary General Meeting (EGM) for Anteris Technologies Ltd, including the Notice of Meeting, Explanatory Memorandum, Proxy Voting Form, and related materials. It details the meeting date, location, agenda items (approval of option grants to directors and executives), voting exclusions, and procedural information. The content is focused on informing shareholders about the meeting and the resolutions to be voted on, rather than reporting financial results or management commentary. The document is lengthy (15,000 characters) and contains the full notice and explanatory memorandum, which are typical for meeting notices. This fits the category of Proxy Solicitation & Information Statement (PSI), as it provides materials sent to shareholders to inform and request votes for the meeting. It is not an Annual Report, Management Report, or Earnings Release, nor is it a simple announcement of a report publication. Therefore, the correct classification is PSI with high confidence.
2023-08-06 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.